Posters

Effective mydriasis during phacoemulsification in the assessment of the surgeon and the patient

Poster Details

First Author: T.Tomczyk POLAND

Co Author(s): E. Mrukwa -Kominek   M. Dorecka                 

Abstract Details

Purpose:

The aim of the study was to assess the effectiveness of mydriasis during phacoemulsification of cataracts with the use of Mydrane in patients after the use of local pharmacological mydriasis and patients without prior pharmacological mydriasis based on our own material taking into account the opinions of surgeons.

Setting:

Department of Ophthalmology Medical University of Silesia in Katowice

Methods:

The analysis included 427 patients admitted during the first treatment week for phacoemulsification, divided into two subgroups. The first one consisted of 299 patients whose procedure was performed on the day of admission. The second group consisted of 118 patients admitted for two- and three-day stays. The effectiveness of mydriatic was assessed in both groups considering the width of the pupil, : >6mm and <6mm, as well as in terms of the presence of iris-lens adhesions. The analysis also presents the effectiveness of the Mydrane preparation after prior application of pharmacological agents.

Results:

In both study groups, the effectiveness of Mydrane was not worse than that of topical pharmacological mydriasis(7,26mm in Group 1 vs. 7,48 in Group 2). In the majority of cases, Mydrane administered during the operation widened the pupil of the operated patient in whom drip mydriatics were applied. Surgeons definitely positively (93,8% on Likert scale) assessed the speed of action of the drug Mydrane on obtaining stable mydriasis during cataract phacoemulsification. Surgeons positively  (90.2% on Likert scale ) responses that mydriasis was stable after treatment with Mydrane.

Conclusions:

Mydrane dilates the pupil no less than the standard used  pharmacological mydriasis. Mydriasis after Mydrane is more stable compared to mydriasis after drops in the opinion of surgeons.

Financial Disclosure:

None